Abstract: J&J has been at the forefront of the recent pharmaceutical industry trend toward more transparency and sharing of clinical trials data; committing early on to make its data available for both internal and external innovation. Janssen is also committed to protecting patient privacy and giving individuals a voice on how their data is used and disclosed.
This presentation will outline Janssen’s data sharing initiatives and describe how it is using leading-edge privacy enhancing technologies (PETs) to mitigate privacy risks and find the right balance between innovation and privacy.
The move to adding Synthetic clinical trial data to the available PETs has vastly increased the number of use cases and has opened a new level of sharing clinical trial data within the company.
Abstract: Real-world data (RWD) are increasingly recognised as playing an important role in guiding drug development and understanding healthcare delivery. This is in part due to the growing availability of RWD sources and the advances in health informatics.
However, access to patient-level data, particularly in Europe and Asia, is complex due to governance rules to protect patient privacy. This presentation will describe use cases for leveraging synthetic data in order to accelerate analytics on otherwise restricted data sources and gain insights to inform patient care.